Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Systematic Review of Secondary Primary Malignancies (SPMs) in Patients Treated with Chimeric Antigen Receptor T-Cell (CAR-T) Therapies

Mounzer E Agha, Sarah McGregor, Kevin C De Braganca, Tamar Lengil, Victoria Alegria, Denise De Wiest, Matthew Perciavalle, Ravi Potluri, Sandip Ranjan, Ahmed Mohamed, Helen Pai, Todd Bixby, Zaina P Qureshi, Peter M. Voorhees

Blood (2024) 144 (Supplement 1): 7583.

https://doi.org/10.1182/blood-2024-199931

Published: 2024

Journal Articles

Treatment Outcomes and Prognostic Factors with Lenalidomide, Bortezomib, and Dexamethasone (RVd) Alone Versus Rvd Plus Autologous Stem Cell Transplantation (ASCT) in African American (AA) Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) in the Determination Phase 3 Trial

Blood (2023) 142 (Supplement 1): 4762.

https://doi.org/10.1182/blood-2023-181032

Published: 2023

Journal Articles

The Phase 2 CARTITUDE-2 Trial: Updated Efficacy and Safety of Ciltacabtagene Autoleucel in Patients with Multiple Myeloma and 1-3 Prior Lines of Therapy (Cohort A) and with Early Relapse after First Line Treatment (Cohort B)

Blood (2023) 142 (Supplement 1): 1021.

https://doi.org/10.1182/blood-2023-178882

Published: 2023

Journal Articles

Single Agent Gemtuzumab Ozogamicin (Mylotarg) Can Induce Hematologic Remissions in Patients with Refractory Acute Myelogenous Leukemia (AML) Relapse Following Allogeneic Stem Cell Transplantation but May Precipitate Acute Graft-Versus-Host Disease (GVHD).

Mounzer E. Agha, MD, Anastasios Raptis, MD, Sarah B. Miller, Michelle Taylor, Markus Y. Mapara, MD, PhD

Blood (2005) 106 (11): 5405.

https://doi.org/10.1182/blood.V106.11.5405.5405

Published: 2005

Journal Articles

Outpatient High-Dose Chemotherapy and Autologous Hematopoietic Cell Transplantation for Multiple Myeloma Is Associated with a Low Infection Safety Profile.

Mounzer E. Agha, M.D., Andrew M. Yeager, M.D., Carol Evans, M.D., Nikol Borkowski, P.A.-C., Anne Marie Scekeres, R.N., Sarah Miller, P.A.-C., Cheryl Tompkins, C.R.N.P., Rowena Schwartz, Pharm.D., Albert D. Donnenberg, Ph.D., Jeffrey Shogan, M.D.

Blood (2004) 104 (11): 5070.

https://doi.org/10.1182/blood.V104.11.5070.5070

Published: 2004

Journal Articles

Infection Is the Major Cause of Mortality after Nonmyeloablative Unrelated Bone Marrow Transplantation with Alemtuzumab, Fludarabine and Melphalan.

Michael P. Carroll, M.D., Diane BuchBarker, M.D., Rowena Schwartz, Pharm.D., Mounzer E. Agha, M.D., Cheryl Tompkins, C.R.N.P., Kristen Baileys, C.R.N.P., Kathleen O’Connell, R.N., Albert D. Donnenberg, Ph.D., Andrew M. Yeager, M.D.

Blood (2004) 104 (11): 5165.

https://doi.org/10.1182/blood.V104.11.5165.5165

Published: 2004

Journal Articles

Single Agent Gemtuzumab Ozogamycin (Mylotarg) Is Effective in Inducing Hematologic Remission in Elderly Patients with Normal Cytogenetics.

Mounzer E. Agha, MD, Miller Sarah, PA-C, Howard Kirkland, MD, Theodore L. Crandall, MD, John W. Mucenski, PharmD.

Blood (2004) 104 (11): 4402.

https://doi.org/10.1182/blood.V104.11.4402.4402

Published: 2004

NARROW

Systematic Review of Secondary Primary Malignancies (SPMs) in Patients Treated with Chimeric Antigen Receptor T-Cell (CAR-T) Therapies

Treatment Outcomes and Prognostic Factors with Lenalidomide, Bortezomib, and Dexamethasone (RVd) Alone Versus Rvd Plus Autologous Stem Cell Transplantation (ASCT) in African American (AA) Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) in the Determination Phase 3 Trial

The Phase 2 CARTITUDE-2 Trial: Updated Efficacy and Safety of Ciltacabtagene Autoleucel in Patients with Multiple Myeloma and 1-3 Prior Lines of Therapy (Cohort A) and with Early Relapse after First Line Treatment (Cohort B)

Single Agent Gemtuzumab Ozogamicin (Mylotarg) Can Induce Hematologic Remissions in Patients with Refractory Acute Myelogenous Leukemia (AML) Relapse Following Allogeneic Stem Cell Transplantation but May Precipitate Acute Graft-Versus-Host Disease (GVHD).

Outpatient High-Dose Chemotherapy and Autologous Hematopoietic Cell Transplantation for Multiple Myeloma Is Associated with a Low Infection Safety Profile.

Infection Is the Major Cause of Mortality after Nonmyeloablative Unrelated Bone Marrow Transplantation with Alemtuzumab, Fludarabine and Melphalan.

Single Agent Gemtuzumab Ozogamycin (Mylotarg) Is Effective in Inducing Hematologic Remission in Elderly Patients with Normal Cytogenetics.

Email alerts

ASH Publications

American Society of Hematology

Systematic Review of Secondary Primary Malignancies (SPMs) in Patients Treated with Chimeric Antigen Receptor T-Cell (CAR-T) Therapies

Treatment Outcomes and Prognostic Factors with Lenalidomide, Bortezomib, and Dexamethasone (RVd) Alone Versus Rvd Plus Autologous Stem Cell Transplantation (ASCT) in African American (AA) Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) in the Determination Phase 3 Trial

The Phase 2 CARTITUDE-2 Trial: Updated Efficacy and Safety of Ciltacabtagene Autoleucel in Patients with Multiple Myeloma and 1-3 Prior Lines of Therapy (Cohort A) and with Early Relapse after First Line Treatment (Cohort B)

Single Agent Gemtuzumab Ozogamicin (Mylotarg) Can Induce Hematologic Remissions in Patients with Refractory Acute Myelogenous Leukemia (AML) Relapse Following Allogeneic Stem Cell Transplantation but May Precipitate Acute Graft-Versus-Host Disease (GVHD).

Outpatient High-Dose Chemotherapy and Autologous Hematopoietic Cell Transplantation for Multiple Myeloma Is Associated with a Low Infection Safety Profile.

Infection Is the Major Cause of Mortality after Nonmyeloablative Unrelated Bone Marrow Transplantation with Alemtuzumab, Fludarabine and Melphalan.

Single Agent Gemtuzumab Ozogamycin (Mylotarg) Is Effective in Inducing Hematologic Remission in Elderly Patients with Normal Cytogenetics.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only